Pharmacogenomics: The Genomics of Drug Response
Open Access
- 1 January 2000
- journal article
- review article
- Published by Hindawi Limited in Yeast
Abstract
Pharmacogenomics is defined as the study of the association between genetics and drug response. This is a rapidly expanding field with the hope that, within a few years, prospective genotyping will lead to patients being prescribed drugs which are both safer and more effective (‘the right drug for the right patient’, or personalized medicine). There are many existing examples in the literature of strong associations between genetic variation and drug response, and some of these even form the basis of accepted clinical tests. The molecular basis for some of these associations is described, and includes examples of variation in genes responsible for absorption and metabolism of the drug, and in target and disease genes. However, there are many issues surrounding the legal, regulatory and ethical framework to these studies that remain unanswered, and a huge amount of education both for the public and haelthcare professionals will be needed bafore the results of this new madicine can be widely accepted.Keywords
This publication has 33 references indexed in Scilit:
- GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUESDrug Metabolism Reviews, 1999
- Revolution through Genomics in Investigative and Discovery ToxicologyToxicologic Pathology, 1999
- Pharmacogenetics of the 5‐lipoxygenase pathway in asthmaClinical and Experimental Allergy, 1998
- Genetic Variation as a Guide to Drug DevelopmentScience, 1998
- Angiotensin-Converting Enzyme Gene Polymorphism Determines the Antiproteinuric and Systemic Hemodynamic Effect of Enalapril in Patients with Proteinuric Renal DiseaseKidney and Blood Pressure Research, 1998
- Why pharmacogenomics? Why now?Nature Biotechnology, 1998
- Pharmacogenomics: Will the regulators approve?Nature Biotechnology, 1998
- Getting the right drug into the right patientNature Biotechnology, 1997
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960
- FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVELThe Lancet, 1956